Autolus Therapeutics PLC 8-K Filing

Ticker: AUTL · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001730463

Autolus Therapeutics PLC 8-K Filing Summary
FieldDetail
CompanyAutolus Therapeutics PLC (AUTL)
Form Type8-K
Filed DateMar 27, 2026
Pages3
Reading Time3 min
Key Dollar Amounts$0.000042
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Autolus Therapeutics PLC (ticker: AUTL) to the SEC on Mar 27, 2026.

What are the key financial figures in this filing?

Key dollar amounts include: $0.000042 (nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec).

How long is this filing?

Autolus Therapeutics PLC's 8-K filing is 3 pages with approximately 826 words. Estimated reading time is 3 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2026-03-27 08:02:10

Key Financial Figures

  • $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec

Filing Documents

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions. On March 27, 2026, Autolus Therapeutics plc (the "Company") announced its financial results for the year ended December 31, 2025 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In connection with its conference call on March 27, 2026 to discuss its results for the year ended December 31, 2025, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated March 2 7, 2 026 99.2 Corporate Presentation dated March 27 , 202 6 104 Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: March 27, 2026 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.